Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have been shown to cause life-threatening toxicity such as immune checkpoint inhibitor-related pneumonitis (CIP). Our previous stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Yencheng, Zhou, Jiebai, Hsu, Shujung, Ding, Ning, Li, Jiamin, Zhang, Yong, Xu, Xiaobo, Tang, Xinjun, Wei, Tianchang, Zhu, Zhengfei, Chu, Qian, Neal, Joel W., Wu, Julie Tsu-Yu, Song, Yuanlin, Hu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902097/
https://www.ncbi.nlm.nih.gov/pubmed/35280322
http://dx.doi.org/10.21037/tlcr-22-72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902097/
https://www.ncbi.nlm.nih.gov/pubmed/35280322
http://dx.doi.org/10.21037/tlcr-22-72

Ejemplares similares